8-K
filed February 22, 2023, 6:59 PM ET
ticker LIVN
CIK 0001639691
earnings
confidence high
sentiment positive
materiality 0.70
LivaNova Q4 revenue up 6.2% constant currency; adjusted EPS $0.81
LivaNova PLC
2022-FY EPS reported
-$1.61
revenue$1,021,805,000
- Q4 revenue $274.9M (+6.2% constant currency); GAAP EPS $0.03, adjusted EPS $0.81.
- FY2022 revenue $1.02B (+2.9% constant currency); GAAP loss per share $1.61, adjusted EPS $2.39.
- First clinical cases of Essenz perfusion system completed; LifeSPARC ECMO 510(k) cleared.
- FDA Warning Letter for Munich facility and 3T Heater-Cooler closed out.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.7
LivaNova PLC updated its FY2023 guidance (initiated).
- Period
- FY2023
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
LivaNova PLC reported Q4 2022 results: revenue $274.9 million, EPS $0.03.
- Period
- Q4 2022
- Revenue
- $274.9 million
- EPS
- $0.03
- Result
- reported results
Exact text from the filing
Fourth-quarter revenue of $274.9 million increased 1.8 percent on a reported basis and 6.2 percent on a constant-currency basis, as compared to the prior-year period • Fourth-quarter U.S. GAAP diluted earnings per share was $0.03 and adjusted diluted earnings per share was $0.81
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
LivaNova PLC reported FY2022 results: revenue $1.02 billion, EPS $1.61.
- Period
- FY2022
- Revenue
- $1.02 billion
- EPS
- $1.61
- Result
- reported results
Exact text from the filing
Full-year 2022 revenue of $1.02 billion decreased 1.3 percent on a reported basis and increased 2.9 percent on a constant-currency basis, as compared to the prior year • Full-year 2022 revenue, excluding revenue from the Heart Valve business which was divested effective June 1, 2021, increased 2.3 percent on a reported basis and 6.7 percent on a constant-currency basis, as compared to the prior year • Full-year 2022 U.S. GAAP diluted loss per share was $1.61 and adjusted diluted earnings per share was $2.39
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.